Use of GLP-1 drugs has expanded rapidly in the United States as medications such as Wegovy, Ozempic and Zepbound move further into mainstream obesity and diabetes care. That trend is now showing up on college campuses, where recent reporting has described growing student interest in the drugs for weight loss, particularly among young women navigating appearance pressure and social competition.
Campus demand comes into clearer view
College students are becoming a more visible part of the GLP-1 market, with Yahoo Health and AOL reporting on September 20 that some students, especially women involved in sorority recruitment, are turning to the injections as weight-loss tools. The coverage, which cited market research and campus anecdotes, said use is rising among younger adults even as a comprehensive national count for college-specific prescribing has not been publicly released.
Broader national data show why campuses are part of the conversation. FAIR Health said prescriptions for GLP-1 drugs among commercially insured adults ages 18 to 39 rose 587.8% between 2019 and 2024, increasing from 0.19% of patients to 1.33%. KFF reported in May 2024 that about 12% of U.S. adults said they had ever taken a GLP-1 drug and 6% said they were currently using one.
Those figures do not isolate enrolled college students, and no federal agency has published a nationwide campus-by-campus breakdown. Still, recent cultural reporting has made clear that student demand is no longer limited to medical settings focused strictly on diabetes treatment. The medications are increasingly part of conversations about body image, appearance and weight management among young adults.
The clearest confirmed impact is not a national school-by-school tally but a growing campus presence in student health conversations. Reporting from Salt Lake Community College in August found student health staff were hearing more questions about drugs such as Ozempic and Wegovy, reflecting how the medications are entering routine wellness discussions among students.
What remains unknown is the full scale of use at individual universities. Colleges generally have not released broad counts of how many students are prescribed GLP-1 drugs, how many obtain them through outside telehealth providers, or how many are using compounded versions. That leaves a gap between the attention the drugs are receiving and the public data available to measure campus uptake.
For students, access also varies sharply. Some obtain the drugs through traditional medical channels tied to obesity or diabetes care, while others report looking to online providers or self-pay options. A 2026 medRxiv preprint on adult GLP-1 use found that among weight-loss-indicated users, many reported nontraditional access routes, including online providers, compounding and limited insurance coverage, a pattern that may help explain how the drugs are reaching younger adults.
The context is a combination of medical expansion, social visibility and mental-health concern. The Food and Drug Administration approved Wegovy for adolescents ages 12 and older in late 2022, and the American Academy of Pediatrics has said pharmacotherapy can be part of obesity treatment for adolescents when used with lifestyle treatment. Those changes widened the medical framework around anti-obesity drugs before many current college students even arrived on campus.
At the same time, researchers and clinicians are warning that enthusiasm around weight loss can collide with body-image pressures common in late adolescence and early adulthood. The American Psychological Association reported this year on a study of 225 college students that found those most interested in trying GLP-1 drugs, and most willing to tolerate side effects, also reported higher body shame and weight concerns.
That does not mean all student use is inappropriate or unsafe. It does mean colleges, clinicians and families are confronting a medication trend that is arriving faster than campus-level public data. The National Eating Disorders Association and recent medical commentary in JAMA Psychiatry and the New England Journal of Medicine have all pointed to the need for screening, monitoring and careful prescribing as GLP-1 use spreads into younger populations.